ARTICLE | Emerging Company Profile
Amyndas: Complement shutdown
Amyndas developing super compstatins for complement-mediated disorders
February 10, 2014 8:00 AM UTC
Transatlantic sister companies Amyndas Pharmaceuticals S.A. and Amyndas Pharmaceuticals LLC are developing therapies to treat complement-mediated disorders that could be more potent than other complement inhibitors, potentially opening up new indications.
Lead candidate Amanden comes from a class of synthetic analogs of the peptidic complement 3 (C3) inhibitor compstatin, which the company calls super compstatins...